| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1001 |
The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia/schizoaffective disorder
|
Harrigan, E.
|
|
1996
|
6 |
S3 |
p. 200-201
2 p.
|
artikel
|
| 1002 |
The efficacy and safety of two fixed doses of ziprasidone in schizophrenia
|
Reeves, K.
|
|
1996
|
6 |
S3 |
p. 201-
1 p.
|
artikel
|
| 1003 |
The efficacy of sertraline in the treatment of major depression
|
Bugarski-Kirola, D.
|
|
1996
|
6 |
S3 |
p. 124-
1 p.
|
artikel
|
| 1004 |
The efficacy of zuclopenthixol acetate in the treatment of psychtic patients
|
Dilbaz, N.
|
|
1996
|
6 |
S3 |
p. 60-
1 p.
|
artikel
|
| 1005 |
The epidemiology of psychiatric disorders in HIV infection: Depression, mania and dementia
|
Lyketsos, C.G.
|
|
1996
|
6 |
S3 |
p. 31-
1 p.
|
artikel
|
| 1006 |
The functional neuroanatomy of prefrontal cortex: Implications for psychosurgery
|
Geffen, L.B.
|
|
1996
|
6 |
S3 |
p. 230-
1 p.
|
artikel
|
| 1007 |
The 5-HT1A receptor antagonist WAY-100635 enhances the behavioural effects of SSRIs
|
Dourish, C.T.
|
|
1996
|
6 |
S3 |
p. 16-17
2 p.
|
artikel
|
| 1008 |
The incidence of neutropenia and agranulocytosis in patients treated with clozapine in the UK and Ireland
|
Atkin, K.
|
|
1996
|
6 |
S3 |
p. 172-
1 p.
|
artikel
|
| 1009 |
The influence of ect on olfactory memory
|
Sirota, Pinkhas
|
|
1996
|
6 |
S3 |
p. 182-
1 p.
|
artikel
|
| 1010 |
The influence of fluoxetine on memory, anxiolytic activity and locomotor function in rats
|
Nowakowska, E.
|
|
1996
|
6 |
S3 |
p. 190-
1 p.
|
artikel
|
| 1011 |
The influence of morning and evening dosing on the pharmacokinetics of flesinoxan
|
Van Harten, J.
|
|
1996
|
6 |
S3 |
p. 40-
1 p.
|
artikel
|
| 1012 |
The influence of selected quinolones on central action of ethyl alcohol in laboratory animals
|
Strzelec, J.
|
|
1996
|
6 |
S3 |
p. 2-
1 p.
|
artikel
|
| 1013 |
The influence of testenate on the brain functional condition of aging
|
Koldunov, V.
|
|
1996
|
6 |
S3 |
p. 188-
1 p.
|
artikel
|
| 1014 |
The influense of ketamine pharmacokinetics on the activity of neurotransmitter systems in humans under surgical stress
|
Davydova, N.A.
|
|
1996
|
6 |
S3 |
p. 134-
1 p.
|
artikel
|
| 1015 |
The inositol depletion hypothesis: Promise and problems
|
Belmaker, R.H.
|
|
1996
|
6 |
S3 |
p. 95-96
2 p.
|
artikel
|
| 1016 |
The integration of intrinsic properties and synaptic inputs in locus coeruleus
|
Williams, J.T.
|
|
1996
|
6 |
S3 |
p. 167-168
2 p.
|
artikel
|
| 1017 |
The integrity of serotonin function and sensitization to cocaine
|
Cunningham, K.A.
|
|
1996
|
6 |
S3 |
p. 161-
1 p.
|
artikel
|
| 1018 |
The level of glutamine synthetase in Alzheimer's disease brain
|
Burbaeva, G.
|
|
1996
|
6 |
S3 |
p. 188-
1 p.
|
artikel
|
| 1019 |
The lithium ion: A foundation for psychopharmacological specificity
|
Soares, J.C.
|
|
1996
|
6 |
S3 |
p. 84-
1 p.
|
artikel
|
| 1020 |
The long-term efficacy and safety of paroxetine in panic disorder
|
Judge, R.
|
|
1996
|
6 |
S3 |
p. 207-
1 p.
|
artikel
|
| 1021 |
The mechanism of amyloid β-Peptide (1–42) toxicity in PC12 cells
|
Fagarasan, M.
|
|
1996
|
6 |
S3 |
p. 144-145
2 p.
|
artikel
|
| 1022 |
The mechanisms and clinical relevance of HIV associated brain damage
|
Everall, I.P.
|
|
1996
|
6 |
S3 |
p. 31-
1 p.
|
artikel
|
| 1023 |
The M1 muscarinic agonist xanomeline improves both cognitive and behavioral deficits in Alzheimer's disease
|
Bodick, N.
|
|
1996
|
6 |
S3 |
p. 144-
1 p.
|
artikel
|
| 1024 |
The modified dexamethasone suppression test (mDST) in chronic PTSD
|
Hopwood, M.
|
|
1996
|
6 |
S3 |
p. 80-81
2 p.
|
artikel
|
| 1025 |
The mRNA expression of G protein subclasses in the methamphetamine-induced behavioral sensitization
|
Iwasa, Hiroto
|
|
1996
|
6 |
S3 |
p. 120-
1 p.
|
artikel
|
| 1026 |
The need for faster and more effective antidepressants
|
Deakin, J.F.W.
|
|
1996
|
6 |
S3 |
p. 16-
1 p.
|
artikel
|
| 1027 |
The neurochemical and behavioural effects of the isomers of mirtazapine in normal rats
|
McGrath, C.
|
|
1996
|
6 |
S3 |
p. 53-
1 p.
|
artikel
|
| 1028 |
The neurochemical and endocrine actions of interleukin-1
|
Dunn, A.J.
|
|
1996
|
6 |
S3 |
p. 249-
1 p.
|
artikel
|
| 1029 |
The neurodevelopmental hypothesis of schizophrenia: A critical clinical perspective
|
Weinberger, D.R.
|
|
1996
|
6 |
S3 |
p. 169-
1 p.
|
artikel
|
| 1030 |
The neuropathology of schizophrenia: Autoradiographic and in situ hybridization studies
|
Kleinman, J.E.
|
|
1996
|
6 |
S3 |
p. 92-93
2 p.
|
artikel
|
| 1031 |
Theoretical considerations of dose/concentration/effect relationships: Direct and indirect pharmacokinetic/dynamic models
|
DeVane, C.L.
|
|
1996
|
6 |
S3 |
p. 81-82
2 p.
|
artikel
|
| 1032 |
The ‘organic’ basis of Late-Onset Schizophrenia
|
Sachdev, P.
|
|
1996
|
6 |
S3 |
p. 62-
1 p.
|
artikel
|
| 1033 |
The paroxetine challenge test for in vivo evaluation of serotonin function in man
|
Reist, C.
|
|
1996
|
6 |
S3 |
p. 176-
1 p.
|
artikel
|
| 1034 |
The patient under neuroleptic treatment
|
Lachaux, B.
|
|
1996
|
6 |
S3 |
p. 222-
1 p.
|
artikel
|
| 1035 |
The peculiarities of the meperedine action in early ontogenesis
|
Zlenko, H.
|
|
1996
|
6 |
S3 |
p. 109-
1 p.
|
artikel
|
| 1036 |
The pharmacoeconomics of depression: Evaluating speed of onset as a key variable
|
Langley, P.
|
|
1996
|
6 |
S3 |
p. 220-
1 p.
|
artikel
|
| 1037 |
The pharmacological management of benzodiazepine withdrawal
|
Schweizer, E.
|
|
1996
|
6 |
S3 |
p. 160-
1 p.
|
artikel
|
| 1038 |
The prevention of mortality in bipolar disorder
|
Coppen, A.
|
|
1996
|
6 |
S3 |
p. 219-
1 p.
|
artikel
|
| 1039 |
The psychobiology of female specific mood disorders — Discussion
|
Steiner, M.
|
|
1996
|
6 |
S3 |
p. 88-
1 p.
|
artikel
|
| 1040 |
The quantitative analysis of a haloperidol derivative and its neurotoxic metabolites in baboons
|
Avent, K.
|
|
1996
|
6 |
S3 |
p. 37-
1 p.
|
artikel
|
| 1041 |
Therapeutic advantage of combined amitriptyline/Lithium and fluvoxamine/lithium treatments
|
Miljković, B.
|
|
1996
|
6 |
S3 |
p. 130-
1 p.
|
artikel
|
| 1042 |
Therapeutic effect of yohimbine in organic and non-organic erectile dysfunction
|
Mann, K.
|
|
1996
|
6 |
S3 |
p. 14-
1 p.
|
artikel
|
| 1043 |
Therapeutic strategies directed at the non-cholinergic transmitter systems
|
Robert, P.H.
|
|
1996
|
6 |
S3 |
p. 30-
1 p.
|
artikel
|
| 1044 |
The relationship between clozapine dose and plasma level and side effects
|
Kalali, AH
|
|
1996
|
6 |
S3 |
p. 250-
1 p.
|
artikel
|
| 1045 |
The relationship between negative symptoms and depression in schizophrenia
|
Addington, D.
|
|
1996
|
6 |
S3 |
p. 62-63
2 p.
|
artikel
|
| 1046 |
The relationship between serotonin and melatonin in the rat pineal gland
|
Nathan, P.J.
|
|
1996
|
6 |
S3 |
p. 102-
1 p.
|
artikel
|
| 1047 |
The rima moclobemide: More than an effective antidepressant?
|
Amrein, R.
|
|
1996
|
6 |
S3 |
p. 164-
1 p.
|
artikel
|
| 1048 |
The role of dopamine system in the striatum on the light pulse induced PRCS
|
Fukuyama, H.
|
|
1996
|
6 |
S3 |
p. 103-
1 p.
|
artikel
|
| 1049 |
The role of environmental and cognitive function in the development of behavioral sensitization
|
Ohmori, T.
|
|
1996
|
6 |
S3 |
p. 160-
1 p.
|
artikel
|
| 1050 |
The role of in vivo amygdala dopamine to cocaine self-administration behavior
|
Hurd, Y.L.
|
|
1996
|
6 |
S3 |
p. 67-
1 p.
|
artikel
|
| 1051 |
The role of NMDA systems in the developmental neurobehavioral toxicity of phencyclidine
|
Scalzo, F.M.
|
|
1996
|
6 |
S3 |
p. 28-29
2 p.
|
artikel
|
| 1052 |
The role of the serotonergic system on nocturnal cortisol and prolactin secretion in healthy humans
|
Nathan, P.J.
|
|
1996
|
6 |
S3 |
p. 177-
1 p.
|
artikel
|
| 1053 |
The role of the seta adrenergic system in CCK-4 induced panic symptoms
|
Le Mellédo, J.-M.
|
|
1996
|
6 |
S3 |
p. 114-
1 p.
|
artikel
|
| 1054 |
The role of the suprachiasmatic nuclei (SCN) as a biological clock: Effects of melatoninergic substances
|
Turek, F.W.
|
|
1996
|
6 |
S3 |
p. 34-
1 p.
|
artikel
|
| 1055 |
The serotonin transporter: From molecular pharmacology to therapeutics
|
Langer, S.Z.
|
|
1996
|
6 |
S3 |
p. 86-
1 p.
|
artikel
|
| 1056 |
The SSRI withdrawal syndrome
|
Preskorn, S.
|
|
1996
|
6 |
S3 |
p. 121-
1 p.
|
artikel
|
| 1057 |
The study of differentially expressed molecules in Alzheimer's disease brain
|
Yamada, M.
|
|
1996
|
6 |
S3 |
p. 188-
1 p.
|
artikel
|
| 1058 |
The study of signal transduction during the action of some memory modulators
|
Kulikova, O.G.
|
|
1996
|
6 |
S3 |
p. 147-
1 p.
|
artikel
|
| 1059 |
The treatment of adolescent depression: Where is the evidence?
|
Martin, G.
|
|
1996
|
6 |
S3 |
p. 11-
1 p.
|
artikel
|
| 1060 |
The use of electroconvulsive therapy in young people
|
Walter, G.
|
|
1996
|
6 |
S3 |
p. 11-
1 p.
|
artikel
|
| 1061 |
Thiazide derivatives block rapid AMPA receptordesensitization
|
Rothman, Steven M.
|
|
1996
|
6 |
S3 |
p. 152-
1 p.
|
artikel
|
| 1062 |
Thyroid hormone use in euthyroid patients in medicine, psychiatry, and surgery: A review
|
Prange Jr., A.J.
|
|
1996
|
6 |
S3 |
p. 208-
1 p.
|
artikel
|
| 1063 |
Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg ‘seroquel’ TID
|
Gefvert, O.
|
|
1996
|
6 |
S3 |
p. 74-
1 p.
|
artikel
|
| 1064 |
Timed melatonin administration on circadian rhythms and vigilance states
|
Wirz-Justice, A.
|
|
1996
|
6 |
S3 |
p. 79-
1 p.
|
artikel
|
| 1065 |
Tolcapone therapy improves cognitive functions in nondemented patients with advanced parkinson's disease
|
Meco, G.
|
|
1996
|
6 |
S3 |
p. 131-
1 p.
|
artikel
|
| 1066 |
Tolerability of low dose neuroleptics: A pseudoprospective, blind investigation of flupenthixol
|
Fritze, J.
|
|
1996
|
6 |
S3 |
p. 148-
1 p.
|
artikel
|
| 1067 |
Toxic haloperidol metabolites in human brain
|
Eyles, D.
|
|
1996
|
6 |
S3 |
p. 4-
1 p.
|
artikel
|
| 1068 |
Transient global amnesia-possible aetiopathogenetic mechanisms
|
Bugarski-Kirola, D.
|
|
1996
|
6 |
S3 |
p. 187-
1 p.
|
artikel
|
| 1069 |
Treatment and consequences of relapse in schizophrenia
|
Lieberman, J.A.
|
|
1996
|
6 |
S3 |
p. 25-
1 p.
|
artikel
|
| 1070 |
Treatment of alcohol withdrawal delirium and changes in monoamine
|
Uchimura, N.
|
|
1996
|
6 |
S3 |
p. 44-
1 p.
|
artikel
|
| 1071 |
Treatment of anxiety disorders in rheumatic heart disease
|
Khokhlov, A.
|
|
1996
|
6 |
S3 |
p. 15-
1 p.
|
artikel
|
| 1072 |
Treatment of neuropsychiatric disorders associated with HIV and AIDS
|
Treisman, G.J.
|
|
1996
|
6 |
S3 |
p. 31-
1 p.
|
artikel
|
| 1073 |
Treatment of schizophrenia and schizoaffetive disorder with a combination of clozapine and lithium
|
Bender, S.A.
|
|
1996
|
6 |
S3 |
p. 200-
1 p.
|
artikel
|
| 1074 |
Treatment of severe major depression: A double-blind study of sertraline and clomipramine
|
Lépine, J.
|
|
1996
|
6 |
S3 |
p. 123-124
2 p.
|
artikel
|
| 1075 |
Treatment of social phobia
|
Montgomery, S.A.
|
|
1996
|
6 |
S3 |
p. 149-
1 p.
|
artikel
|
| 1076 |
Treatment of the neuroleptic malignant syndrome by electroconvulsive therapy
|
Seifertová, Dagmar
|
|
1996
|
6 |
S3 |
p. 172-
1 p.
|
artikel
|
| 1077 |
Treatment refractoriness: New strategies
|
Post, RM
|
|
1996
|
6 |
S3 |
p. 251-
1 p.
|
artikel
|
| 1078 |
Treatment refractory depression: Long term issues
|
Keller, M.B.
|
|
1996
|
6 |
S3 |
p. 93-
1 p.
|
artikel
|
| 1079 |
Treatment-resistant depression: Resistant and complicated depression
|
Price, L.H.
|
|
1996
|
6 |
S3 |
p. 93-
1 p.
|
artikel
|
| 1080 |
Treatment with “Deproteinized calves' blood extract” in mild and moderate Alzheimer's
|
Nivataphand, R.
|
|
1996
|
6 |
S3 |
p. 187-
1 p.
|
artikel
|
| 1081 |
Treatment with mirtazapine is not related to complaints of sexual dysfunction
|
Rekers, H.
|
|
1996
|
6 |
S3 |
p. 47-
1 p.
|
artikel
|
| 1082 |
Tricycles and SSRIS enhance adenylate cyclase and cAMP-related behaviors in rat
|
Maeda, H.
|
|
1996
|
6 |
S3 |
p. 55-
1 p.
|
artikel
|
| 1083 |
Tryptophan depletion in recovered depressives and recovered bulimics
|
Smith, K.A.
|
|
1996
|
6 |
S3 |
p. 129-130
2 p.
|
artikel
|
| 1084 |
Twenty-four-hour urinary monoamine excretion in posttrumatic stress disorder
|
Chung, Moonyong
|
|
1996
|
6 |
S3 |
p. 76-77
2 p.
|
artikel
|
| 1085 |
Twenty years of clinical experience with the use of clozapine in severe psychotic patients
|
Ciprian-Ollivier, J.
|
|
1996
|
6 |
S3 |
p. 200-
1 p.
|
artikel
|
| 1086 |
Two open-label, long-term safety studies of sertindole
|
Daniel, D.
|
|
1996
|
6 |
S3 |
p. 61-62
2 p.
|
artikel
|
| 1087 |
Two-year follow-up after treatment of panic disorder with agoraphobia
|
van Balkom, A.J.L.M.
|
|
1996
|
6 |
S3 |
p. 112-
1 p.
|
artikel
|
| 1088 |
Type of onset and personality in panic disorder
|
Hranov, L.
|
|
1996
|
6 |
S3 |
p. 205-
1 p.
|
artikel
|
| 1089 |
Typical antipsychotics: The threshold doses strategy
|
Ortega-Soto, H.A.
|
|
1996
|
6 |
S3 |
p. 199-
1 p.
|
artikel
|
| 1090 |
Typical vs. Atypical antipsychotics in late-life psychosis
|
Jeste, D.V.
|
|
1996
|
6 |
S3 |
p. 27-
1 p.
|
artikel
|
| 1091 |
Ultra-rapid opioid detoxification using narcotic antagonists
|
Kleber, H.D.
|
|
1996
|
6 |
S3 |
p. 162-
1 p.
|
artikel
|
| 1092 |
Use of anticholinergic eye drops in differentiating Alzheimer's disease and depression
|
Schweitzer, I.
|
|
1996
|
6 |
S3 |
p. 143-
1 p.
|
artikel
|
| 1093 |
Use of benzodiazepines in opiate addicted patients — Results of an inquiry in basle
|
Ladewig, D.
|
|
1996
|
6 |
S3 |
p. 2-
1 p.
|
artikel
|
| 1094 |
Use of citalopram, a serotonin selective reuptake inhibitor, in OCD
|
Stein, D.
|
|
1996
|
6 |
S3 |
p. 70-
1 p.
|
artikel
|
| 1095 |
Use of combined SSRIS and moclobemide in treatment-resistant depression
|
Grounds, D.
|
|
1996
|
6 |
S3 |
p. 127-
1 p.
|
artikel
|
| 1096 |
Use of combined SSRIs and moclobemide in treatment-resistant depression
|
Grounds, D.
|
|
1996
|
6 |
S3 |
p. 249-
1 p.
|
artikel
|
| 1097 |
Use of narcotic antagonist in treating opioid addiction
|
Fischman, M.W.
|
|
1996
|
6 |
S3 |
p. 163-
1 p.
|
artikel
|
| 1098 |
Uses of narcotic antagonists in the treatment of addiction
|
Kleber, H.D.
|
|
1996
|
6 |
S3 |
p. 163-164
2 p.
|
artikel
|
| 1099 |
Utility-based measures of health-related quality of life in depression
|
Bennett, K.J.
|
|
1996
|
6 |
S3 |
p. 128-
1 p.
|
artikel
|
| 1100 |
Validation of the french version of PRIME-MD a primary care evaluation of mental disorder
|
Boyer, P.
|
|
1996
|
6 |
S3 |
p. 210-
1 p.
|
artikel
|
| 1101 |
Validity of the concept of dysthymia
|
Waintraub, L.
|
|
1996
|
6 |
S3 |
p. 222-
1 p.
|
artikel
|
| 1102 |
Valproate in migraine prophylaxis
|
Mathew, Ninan T.
|
|
1996
|
6 |
S3 |
p. 27-
1 p.
|
artikel
|
| 1103 |
Variety of lithium benefits
|
Grof, P
|
|
1996
|
6 |
S3 |
p. 249-
1 p.
|
artikel
|
| 1104 |
Weight gain and long term clozapine efficiency
|
Jalenques, I.
|
|
1996
|
6 |
S3 |
p. 170-
1 p.
|
artikel
|
| 1105 |
What if i do? What if i don't? Risk-benefit and ethical issues of neurosurgical treatment for mental disorders
|
Mindus, P.
|
|
1996
|
6 |
S3 |
p. 230-231
2 p.
|
artikel
|
| 1106 |
Will novel antipsychotics be the next standard of care for patients with schizophrenia: A worldwide report on risperidone
|
Grebb, Jack
|
|
1996
|
6 |
S3 |
p. 33-
1 p.
|
artikel
|
| 1107 |
Withdrawal of lorazepam long-term administered using six different plans
|
Lemoine, P.
|
|
1996
|
6 |
S3 |
p. 118-
1 p.
|
artikel
|
| 1108 |
Youth suicide in Victoria: A retrospective study
|
Burrows, G.D.
|
|
1996
|
6 |
S3 |
p. 89-
1 p.
|
artikel
|
| 1109 |
Zotepine in acute exacerbation of schizophrenia: A comparison versus chlorpromazine and placebo
|
Cooper, S.J.
|
|
1996
|
6 |
S3 |
p. 148-
1 p.
|
artikel
|
Tijdschrift beschrijving